This update clarifies that a jury, not the court, said Stratagene should pay the damages. The presiding judge must still weigh in.
 
NEW YORK (GenomeWeb News) — A jury said Stratagene should pay Invitrogen nearly $8 million in damages for infringing its patents, or around four times less than Invitrogen had hoped to win, Stratagene said today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.